Tatjana Heinrich is a highly experienced Group Lead in Preclinical Drug Development with a strong background in Biotechnology. Her expertise lies in Drug Discovery, Project Management, Molecular Biology, Peptide Chemistry, Protein Expression, and Bioinformatics. She holds a PhD in Biochemistry and Molecular Biology from Freie Universität Berlin, showcasing her dedication to advancing this field. Tatjana’s leadership skills and vast experience in this critical domain drive Emyria’s innovative research and development to improve patient outcomes.